UK government to consult on value-based pricing in December
This article was originally published in Scrip
Pharmaceutical companies operating in the UK may soon have a clearer idea of the shape of the new value based pricing (VBP) system for setting the price of drugs. The Department of Health will launch a consultation on proposals for VBP next month, according to the department's Business Plan 2011-2015. The government expects the new system to be up and running in January 2014, ready to replace the current Pharmaceutical Price Regulation Scheme when it comes to an end. The department will actually begin developing the system, together with pharmaceutical companies, next April. Value-based pricing forms part of the UK coalition government's plans to overhaul the National Health System to create a "patient-led NHS" and to improve healthcare outcomes.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.